滋养层细胞表面抗原2（TROP-2）作为新型癌症靶点的出现

Goldenberg等人（周五）研究了这个问题。

www.synapsesocial.com/papers/69cac1a5c138251ffc5f8151 — DOI: https://doi.org/10.18632/oncotarget.25615

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results· 2018 · 17 citations
2. Advantage of yttrium‐90‐labeled over iodine‐131‐labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft· 1997 · 6 citations
3. Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer· 2012 · 107 citations
4. Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys· 2011 · 294 citations
5. RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models· 2016 · 101 citations